Brain function protection in patients with cerebral infarction
Conditions
Interventions
Experimental group:Routine treatment of cerebral infarction+Huperzine A Injection
Control group:Routine treatment of cerebral infarction
Sponsors
The First Affiliated Hospital of Henan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The age is 18 to 70 years old (including 18 and 70 years old), regardless of gender; 2. Patients diagnosed with cerebral infarction according to the "Chinese Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018"; 3. The first onset of cerebral infarction, no previous treatment of thrombolysis and trophic nerve (such as: thrombolytic drugs urokinase, alteplase, reteplase, etc.; nutritional nerve drugs citicoline, edara Feng injection, amitrazine mesylate lobaxin tablets, ganglioside, deproteinized calf blood extract, nerve growth factor, Xingnaojing injection, nalmefene hydrochloride injection, piracetam injection Liquid, etc.); 4. After receiving symptomatic treatment, vital signs are stable, blood pressure, blood oxygen, and heart monitoring reach the control goals: 1) Blood pressure control goals: Systolic blood pressure = 94% or PO2 >= 75mmHg, PCO2 36~44mmHg; 3) Heart monitoring and control goals: Perform electrocardiogram routinely within 24 hours after cerebral infarction, and continue ECG monitoring for more than 24 hours when conditions permit, without using or using drugs that increase the burden of the heart, to avoid heart attacks such as paroxysmal atrial fibrillation or severe arrhythmia; 5. No previous history of obvious respiratory system, circulatory system, liver and kidney disease, cholinesterase deficiency and other infectious diseases; 6. The subjects guardian and/or subject volunteered to join the study and signed a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with other neurological diseases; 2. Patients with seizures, angina, bronchial asthma, mechanical intestinal obstruction, renal insufficiency, and urinary tract obstruction; 3. Patients with brain tumor, craniocerebral trauma, and old stroke disease; 4. Patients with previous severe aphasia, visual impairment, hearing impairment, etc. who cannot cooperate with the scale examination; 5. Patients with a history of taking antipsychotic drugs, sedative drugs, narcotic analgesics; 6. Patients with a history of alcoholism; 7. Patients who are intolerant or allergic to this study drug; 8. Female patients during pregnancy or lactation; 9. Patients who participated in other clinical trials within 3 months before screening; 10. Other situations that the investigator thinks are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIHSS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| GCS score;mRS score;Wake-up time (if applicable);Metabolomics; | — |
Countries
China
Contacts
Public ContactChen wenwu
The First Affiliated Hospital of Henan University
Outcome results
None listed